Epithelial-Mesenchymal Transition and Lung Cancer: Mechanism for Resistance to EGFR-TKIs?
Despite all of the encouraging clinical results with molecularly targeted therapies against non-small cell lung cancer, there are still important and significant questions that continue to vex. The discovery of activating mutations in EGFR radically changed the treatment options for...
Source: The Daily Sign-Out - Category: Pathologists Authors: Mark D. Pool, M.D. Tags: Biomarkers in Lung Cancer Epithelial-to-Mesenchymal Transition Non small cell lung cancer Source Type: blogs
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Pathologists